Navigation Links
Environmental estrogens can cause breast cancer

Exposure to environmental estrogen 4-nonylphenol may increase the incidence// of breast cancer.

Dr. William S. Baldwin and research team from University of Texas has reported that risk of breast cancer may be increased if exposed to environmental estrogen 4-nonylphenol. 4-nonylphenol is an estrogen like chemical which is released from cleaning agents, from industrial wastes of textiles, paper, plastic, cosmetic and agricultural chemical industries.

The study was carried out in mice experiments by inducing the chemical 4-nonylphenol into mice and all the 5 mice induced with 4-nonylphenol developed tumors in the breast. The study shows that exposure to environmental estrogen 4-nonylphenol increased the risk of breast cancer in mice. The study also showed that after administration of 4-nonylphenol the mice had a reduced latency period before development of tumor after induction. They had a shortened latency period for tumor development and also the metastasis spread to the lung increased after induction of 4-nonylphenol.

This research is another example demonstrating that estrogen-like chemicals in the environment "has the ability to cause cancer," Dr. William S. Baldwin from University of Texas at El Paso, El Paso, Texas told Reuters Health. "Whether they really do or not is unknown." The animals' exposure in this study was much higher than that encountered in the environment.

Breast cancer is one of the common cancers in women and in which genetic and environmental factors plays an important role in causing breast cancer. Many factors increase the estrogen levels in the female, environmental factors also increase these hormone levels, which is thought to be an important factor for breast cancer occurrence.

Though the dosage of 4-nonylphenol given to mice is much greater than the dosage what humans gets exposed in their daily life. The dosage given to mice is 1000 times more the level of human exposure. Still this study
'"/>




Page: 1 2

Related medicine news :

1. Environmental Factors Found To Have An Impact On The Sex of A Child
2. Environmental Factors Found To Have An Impact On The Sex of A Child
3. Athletes Are More Prone To Environmental Pollutants Due To Choice Of Diet
4. Industrial and Environmental pollutants increase diabetes risk
5. Environmental Abuse Causes Health Hazards
6. Genes And Environmental Factors Determine Stress Response
7. Air Pollution in Tamil Nadu is a Cause of Concern for Environmentalists
8. WHO Outlines the Link between Environmental Hazards and Disease
9. Environmental Factors Leads to Obesity in Rural Communities
10. Environmental Factors Trigger Onset of Diabetes
11. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
Post Your Comments:
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...nce of Oral and Overall Health, HARRISBURG, Pa., ...ted,Concordia Dental is celebrating National Smile...a and the British Dental Health Foundation to,prom...h. Beginning May 18,this year,s event is launchin...it the largest independent international dental he...
(Date:5/16/2008)...nefit from calcitriol, an oral form , , ...d vitamin D may cut the risk of death for people w...bout one quarter, a new study suggests. , Duri...hose being treated with calcitriol, an oral form o...eath lowered by 26 percent when compared with thos...
(Date:5/16/2008)...niors and People With,Disabilities, OAKLAND, Cali...,homecare workers across the state are outraged by...rs of service, wages and benefits,which would for...d the,people they serve deeper into poverty. They ...nd people with disabilities from Schwarzenegger,s,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
... found a herb used in traditional Indian medicine ...nsulin levels // in a manner similar to prescripti...a herb called salacia oblonga, which is native to ...oblonga binds to intestinal enzymes that break dow...
...reveals that a compound in carrots may reduce the ...ve found // that falcarinol, a natural pesticide f...duces the risk of developing cancer. Falcarinol pr...h as licorice rot, which causes black spots on the...
...y that looked at how in utero exposures affect the... say, larger babies // have a higher risk of devel...ay associations between larger birth weight and in... proposed, but there have been few studies to exam...
...disease are more likely to suffer from atheroscler...d to heart attack // or stroke shows latest resear...ria levels in the mouths of 657 people who had no ...hickness of the subjects' carotid artery, used to ...
Other Medicine News:
(Date:5/16/2008)...l Biomarkers -- for Lung Cancer Diagnosis and, Ide...r of Unknown Primary ...Types With High Sensitivity and, Specificity and...ncer Results of microRNA Signature to Identify Ti...ding 90% and Specificity of 99%, REHOVOT, Israel ...
(Date:5/15/2008)...May 15 /- Eisai Corporation of North,...cal data abstracts about,compounds in the company,...ical oncology research have been accepted for pres...n Society of Clinical Oncology (ASCO),taking plac... variety of abstracts on Eisai marketed products a...
(Date:5/15/2008)...at ASCO Showed Acceptable Tolerability Profile, ...opathy, WOODCLIFF LAKE, N.J., May 15 /PRNewswire/...bulin mesylate (E7389) demonstrated activity in a,...y advanced or metastatic,breast cancer, according ...al. The study also suggests that eribulin mesylate...
(Date:5/15/2008)... 15 /- Sanofi-aventis,(EURO...ings from the,landmark ATHENA study showed Multaq(...tment of patients with atrial fibrillation or atri...ospitalizations or death from any,cause by a stati...he study,primary endpoint. The ATHENA results will...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results 11118 1Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 1Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 2Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 3Barr Launches Generic Fosamax 28R 29 Tablets 70 mg 3067 4Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension 11113 1Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension 11113 2SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 1SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 2SpringCM Improves Contract Management Efficiency for Medical Staffing Agency 11109 3
...orted by the,National Institutes of Healths Nati...and Skin Diseases (NIAMS) shows that the,anticon... certain,types of seizures, can be an effective ...ated with the common, often hard-to-treat,chroni...onsored, randomized, double-blind clinical trial,...
...via COMTEX News,Network) -- Myriad Genetics, Inc. ...ww.myriad.com/">www.myriad.com ),announced today t...taggered Start" and a "Randomized Withdrawal" clin...d Start" clinical trial,design at the Alzheimer,s ..., 2007, in Washington, D.C. The analysis demonstra...
Other Medicine Technology:Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches.
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches.
Medicine Products: